Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction.
about
Biomarkers in heart failure with preserved ejection fractionState of the Art: Newer biomarkers in heart failureSoluble ST2 Testing: A Promising Biomarker in the Management of Heart FailureRole of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trialPlasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction StudyNovel biomarkers for cardiovascular risk prediction.The prognostic value of plasma soluble ST2 in hospitalized Chinese patients with heart failure.Biomarkers of coronary artery disease: the promise of the transcriptome.ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease.Altered serum levels of IL-33 in patients with advanced systolic chronic heart failure: correlation with oxidative stress.Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study.Soluble ST2 protein in chronic heart failure is independent of traditional factors.Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling.Soluble ST2 for Prediction of Heart Failure and Cardiovascular Death in an Elderly, Community-Dwelling PopulationComparison Between Soluble ST2 and High-Sensitivity Troponin I in Predicting Short-Term Mortality for Patients Presenting to the Emergency Department With Chest Pain.Soluble ST2 predicts elevated SBP in the communityNovel biomarkers in acute heart failure.Role of IL-33 in inflammation and disease.The Presage(®) ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2.ST2 as a cardiovascular risk biomarker: from the bench to the bedside.New and emerging biomarkers in left ventricular systolic dysfunction--insight into dilated cardiomyopathy.Positioning of inflammatory biomarkers in the heart failure landscape.Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction.Prognostic markers for acute heart failure.Circulating biomarkers in patients with heart failure and preserved ejection fraction.The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers.A novel cardiac bio-marker: ST2: a review.Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction.The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management.Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use.Clinical relevance of sST2 in cardiac diseases.ST2 and Galectin-3: Ready for Prime Time?Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction.ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality.Soluble ST2 levels in patients with cardiogenic and septic shock are not predictors of mortality.Gene expression and levels of IL-6 and TNFα in PBMCs correlate with severity and functional class in patients with chronic heart failure.ST2 Predicts Mortality and Length of Stay in a Critically Ill Noncardiac Intensive Care Unit Population.Novel plasma and imaging biomarkers in heart failure with preserved ejection fraction.Serum PINP, PIIINP, galectin-3, and ST2 as surrogates of myocardial fibrosis and echocardiographic left venticular diastolic filling propertiesIn-depth proteomic profiling of left ventricular tissues in human end-stage dilated cardiomyopathy.
P2860
Q26768192-B2BD87EA-571E-4F26-891D-4336735B1F04Q27027899-9825F864-2013-445E-A007-A4BDEFC879EFQ28066438-30CE34E1-4BAD-4070-972E-D52425072E8DQ28253329-4C9320DC-43AE-46F0-8137-E2BDDE3A27A4Q31036336-02637C33-0361-49C1-853E-C88CD7507450Q33615459-C3B2A8D5-67BD-49B8-807E-D7E2F30E53D0Q34408467-C032FC3D-5B1F-4548-A806-B853A1F2FCE7Q34507146-2409346E-CE95-4F97-85FD-1C071CE9E2ECQ36424657-E61AD25C-F489-42F7-AB4C-971A1C5C3A9BQ36445023-97D19266-A900-4F46-AFB7-316E355CB3DFQ36569151-C1A9C156-1B20-49B4-804A-3759BBA4DE0EQ36686088-D1BA4E79-3644-4212-985E-BC0A68189B0BQ37200836-DCCED15C-4C65-4F03-9945-84DC9CB89AADQ37240346-029321AC-D7D3-47B0-9C96-DDDF3C4EC7D8Q37547780-796DE400-3FB0-4FCB-B435-A028008C7C41Q37702150-D0CD0FE5-EE33-4757-A182-F404DEF66E88Q37890908-D0E5B60F-F6BA-4C0D-A988-CFAD8B2078D5Q37922810-6B7E60AF-6159-4282-9E49-BC10CF510C4DQ38068933-9D4C4F13-E374-4733-9DFD-CC78A647D128Q38096251-8EF76A7C-AB00-446E-8E41-D45CE9486E37Q38100987-C7D0ED72-8D52-41D2-9807-CF759D1D7B51Q38105986-E9CFF17C-273F-426F-9741-DC1DDC316BF6Q38110226-DD11B98C-A2E7-4841-B2D4-7AE2836E6911Q38116536-CB457E4F-63AD-4D77-8535-C1CEABD2D158Q38152289-6D9A9F90-1FE0-47C8-AFB9-3710A8FE9FD5Q38154222-29161491-83FC-4ADE-BCC3-B89CD46769F5Q38171069-D3419F03-F0D9-455C-AF66-919BAE939C63Q38380593-892EF295-FE34-4438-88BB-C998D51F6428Q38551693-47B9F55E-B751-4D5B-A386-25AEDD0BF77DQ38614176-3EA7E1B4-ACC8-4E84-9D58-C038CAF5B28DQ38626970-23812FEF-0DA6-4780-BC64-877CB5F5C5F7Q38816590-577A81EF-FA68-47C0-A6F7-91A654C3DCC7Q39127729-92095AC1-E905-419C-A854-4DAAACD6BE00Q39150426-68E8BFC3-C5B5-4359-B46C-A8843EA532C3Q39868169-7E307C36-C78A-4FCD-8194-E5695924E46AQ40058677-94365A52-6499-48AC-B243-F2E0BDBA6400Q40921882-02E2E97E-32B5-43FE-8B5D-68984DD0226BQ40963394-85F797C8-33F4-4225-8051-F2336E63E3FCQ41111574-82139D55-EB2A-4553-83BF-99BEFB0E136DQ41471609-BACBFD5A-4325-4C31-B3A7-351A8F686B37
P2860
Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Usefulness of soluble concentr ...... ventricular ejection fraction.
@ast
Usefulness of soluble concentr ...... ventricular ejection fraction.
@en
type
label
Usefulness of soluble concentr ...... ventricular ejection fraction.
@ast
Usefulness of soluble concentr ...... ventricular ejection fraction.
@en
prefLabel
Usefulness of soluble concentr ...... ventricular ejection fraction.
@ast
Usefulness of soluble concentr ...... ventricular ejection fraction.
@en
P2093
P2860
P1476
Usefulness of soluble concentr ...... ventricular ejection fraction.
@en
P2093
Domingo Pascual-Figal
James Louis Januzzi
Quynh A Truong
Sergio Manzano-Fernández
Thomas Mueller
P2860
P304
P356
10.1016/J.AMJCARD.2010.09.011
P407
P577
2011-01-01T00:00:00Z